PT  - JOURNAL ARTICLE
AU  - J.J. Gemmete
AU  - S.K. Mukherji
TI  - Panitumumab (Vectibix)
AID  - 10.3174/ajnr.A2601
DP  - 2011 Jun 01
TA  - American Journal of Neuroradiology
PG  - 1002--1003
VI  - 32
IP  - 6
4099  - http://www.ajnr.org/content/32/6/1002.short
4100  - http://www.ajnr.org/content/32/6/1002.full
SO  - Am. J. Neuroradiol.2011 Jun 01; 32
AB  - Panitumumab (Vectibix), is a human monoclonal antibody EGFR antagonist indicated as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. This article will present the mechanism of action as well as the clinical role for this monoclonal antibody. c-erbB-1EGFR geneEGFRepidermal growth factor receptorFDAUS Food and Drug AdministrationHERhuman epidermal growth factor receptorKRASKristen rat sarcoma viral oncogene homolog